Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - ruxolitinibum - compresse - ruxolitinibum 5 mg ut ruxolitinibi phosphas, lactosum monohydricum 71.45 mg, cellulosum microcristallinum, carboxymethylamylum natricum a, hydroxypropylcellulosum, povidonum k 30, silica colloidalis anhydrica, magnesii stearas, pro compresso corresp. natrium 0.32 mg. - myelofibrose, polycythaemia vera, akute graft-versus-host-krankheit - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - ruxolitinibum - compresse - ruxolitinibum 15 mg ut ruxolitinibi phosphas, lactosum monohydricum 214.35 mg, cellulosum microcristallinum, carboxymethylamylum natricum a, hydroxypropylcellulosum, povidonum k 30, silica colloidalis anhydrica, magnesii stearas, pro compresso corresp. natrium 0.97 mg. - myelofibrose, polycythaemia vera, akute graft-versus-host-krankheit - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - ruxolitinibum - compresse - ruxolitinibum 20 mg ut ruxolitinibi phosphas, lactosum monohydricum 285.8 mg, cellulosum microcristallinum, carboxymethylamylum natricum a, hydroxypropylcellulosum, povidonum k 30, silica colloidalis anhydrica, magnesii stearas, pro compresso corresp. natrium 1.29 mg. - myelofibrose, polycythaemia vera, akute graft-versus-host-krankheit - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - ruxolitinibum - compresse - ruxolitinibum 10 mg ut ruxolitinibi phosphas, lactosum monohydricum 142.9 mg, cellulosum microcristallinum, carboxymethylamylum natricum a, hydroxypropylcellulosum, povidonum k 30, silica colloidalis anhydrica, magnesii stearas, pro compresso corresp. natrium 0.65 mg. - myelofibrose, polycythaemia vera, akute graft-versus-host-krankheit - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - altri preparati dermatologici - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Unione Europea - italiano - EMA (European Medicines Agency)

novartis europharm limited - ruxolitinib (come fosfato) - myeloproliferative disorders; polycythemia vera; graft vs host disease - agenti antineoplastici - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. policitemia vera (pv)jakavi è indicato per il trattamento di pazienti adulti affetti da policitemia vera, che sono resistenti o intolleranti di hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.

Unione Europea - italiano - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - agenti antineoplastici - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - fedratinibum - capsule rigide - fedratinibum 100 mg ut fedratinibi dihydrochloridum monohydricum, cellulosum microcristallinum silicificatum, natrii stearylis fumaras corresp. natrium 0.18 mg, kapselhülle: gelatina, e 172 (rubrum), e 171, drucktinte: lacca, e 171, propylenglycolum, pro capsula. - primäre oder sekundäre myelofibrose - synthetika

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

s.f. group s.r.l. - itraconazolo - itraconazolo

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

gilead sciences switzerland sàrl - axicabtagenum ciloleucelum zelldispersion di 0.4 – 2 x 10e8 cellule/singola infusione (68 ml) - yescarta - beutel: axicabtagenum ciloleucelum zelldispersion von 0.4 – 2 x 10e8 zellen/einzel-infusionsbeutel (68 ml), natrii chloridum, albuminum umana, cryostor cs10 34 ml corrisp. dimethylis sulfoxidum 5 % v/v, per la preparazione. - yescarta ist eine gegen cd19 gerichtete, genetisch modifizierte autologe t-zell-immuntherapie und wird angewendet bei erwachsenen patienten zur behandlung von; • diffusem grosszelligem b-zell-lymphom (dlbcl) oder high-grade-b-zell-lymphom (hgbl), das auf die erstlinien-chemoimmuntherapie refraktär ist oder innerhalb von 12 monaten nach der erstlinien-chemoimmuntherapie rezidiviert; • rezidiviertem oder refraktärem (r/r) dlbcl oder primärem mediastinalem grosszelligem b-zell-lymphom (pmbcl) nach zwei oder mehr systemischen therapielinien. ; • yescarta wird angewendet zur behandlung von erwachsenen patienten mit rezidiviertem oder refraktärem follikulärem lymphom (fl) nach drei oder mehr systemischen therapielinien. - trapianto: gentherapieprodukt